Zacks.com on MSN23d
Novartis Gets CHMP Recommendation for Kisqali in Broader PopulationNovartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...
Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...
MedPage Today on MSN2d
Year in Review: Early Breast CancerNews in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...
Kisqali was approved as a treatment for early breast cancer by the U.S. Food and Drug Administration (FDA) in September 20245. Regulatory reviews for Kisqali as an EBC treatment are ongoing ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
Novartis' strong breast cancer portfolio has the top drug Kisqali, which has put up a spectacular performance. The Zacks Consensus Estimate for Sanofi’s earnings has risen from $4.21 to $4.25 ...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback